Immutep Limited shares are trading higher after the company announced new clinical data from triple combination therapy in INSIGHT-003 trial.
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited shares are trading higher following the announcement of new clinical data from the triple combination therapy in the INSIGHT-003 trial.
May 24, 2023 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited shares are trading higher after the company announced positive clinical data from the INSIGHT-003 trial.
Immutep Limited announced new clinical data from the triple combination therapy in the INSIGHT-003 trial. This positive news is likely to have a short-term positive impact on the company's stock price, as it indicates progress in their clinical trials and potential future success in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100